Literature DB >> 35713769

Inferior Vena Cava Collapsibility Index: A Precise, Noninvasive Tool for Evaluation of Edema in Children with Nephrotic Syndrome.

Hanan El-Halaby1, Ashraf Bakr2, Mohamed El-Assmy1, Hussein Abdelaziz Abdalla3, Marwa Salem4, Riham Eid5.   

Abstract

This study aimed to evaluate available volume status assessment tools in nephrotic syndrome (NS). Sixty children with INS were subdivided into hypovolemic and nonhypovolemic groups based on fractional excretion of sodium (FeNa%); all were studied for inferior vena cava collapsibility index (IVCCI), plasma atrial natriuretic peptide (ANP), and body composition monitor (BCM). Forty-four patients had nonhypovolemic and 16 had hypovolemic states. ANP did not differ between both groups. IVCCI was higher in hypovolemic group (p < 0.001) with sensitivity 87.5% and specificity 81.8% for hypovolemia detection, while BCM overhydration (BCM-OH) values were higher in nonhypovolemic group (p = 0.04) with sensitivity = 68.2% and specificity = 75% for detection of hypervolemia. FeNa% showed negative correlation with IVCCI (r =  -0.578, p < 0.001) and positive correlation with BCM-OH (r = 0.33, p = 0.018), while FeNa% showed nonsignificant correlation to ANP concentration. IVCCI is a reliable tool for evaluating volume status in NS and is superior to BCM.
© 2022. The Author(s).

Entities:  

Keywords:  Atrial natriuretic peptide; Body composition monitor; Children; Inferior vena cava; Intravascular volume; Nephrotic syndrome

Mesh:

Substances:

Year:  2022        PMID: 35713769      PMCID: PMC9569288          DOI: 10.1007/s12098-022-04177-1

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   5.319


Introduction

There has been a trend to treat edema of idiopathic nephrotic syndrome (INS) children with albumin and furosemide, which is appropriate for hypovolemic patients; however, in non hypovolemic patients, this can precipitate fluid overload. So, it is critical to differentiate types of edema [1]. The currently available tools to assess volume load including inferior vena cava collapsibility index (IVCCI) [2, 3] and bioimpedance spectroscopy (BIS) technique such as body composition monitor (BCM) [4] and plasma atrial natriuretic peptide (ANP) [5, 6]. However, all 3 tools are scarcely evaluated in INS patients and no cutoff levels available. This study was carried out to evaluate the use of IVCCI, BCM, and plasma ANP levels to differentiate type of edema in INS children.

Material and Methods

Over 3 y, 60 patients were enrolled and classified into hypovolemic and nonhypovolemic groups (nonhypovolemic group was on diuretics at the time of enrollment) based on FeNa%. All investigations were done before any intervention: For inferior vena cava collapsibility index (IVCCI) measurement, the inspiratory and expiratory diameters of the IVC were measured, 2 cm from its entrance into the atrium. Body composition monitoring overhydration (BCM-OH) was done via body composition monitoring (BCM) device (BCM, Fresenius Medical Care D GmbH). Plasma atrial natriuretic peptide (ANP) concentration was measured by enzyme-linked immunosorbent assay (ELISA) technique.

Results

The detailed clinical, laboratory, and volume status assessment variables for both the groups are presented in Table 1. FeNa% showed negative significant correlation with IVCCI (r =  −0.578, p < 0.001) and positive significant correlation with BCM-OH (r = 0.33, p = 0.018), while FeNa% showed nonsignificant correlation to ANP level (p = 0.25). To assess the cutoff value of IVCCI, BCM-OH, and plasma ANP concentration that discriminate the volume states in children with active NS, ROC curves for IVCCI, BCM-OH, and serum ANP were plotted against volume state. The area under the curve (AUC) for hypovolemia detection for ANP level was nondiscriminative (AUC = 0.511). Correlating clinical histories with IVCCI results showed nonsignificant differences between IVCCI values between patients with SSNS and those with SRNS.
Table 1

Clinical and laboratory data of hypovolemic vs. nonhypovolemic patients with active INS at the time of initial enrollment in the study and after resolution of edema

Hypovolemic patients (n = 16)Nonhypovolemic patients (n = 44)p
Age at diagnosis (years)3.08 ± 1.33.8 ± 2.010.2
Age at enrollment (years)6.2 ± 2.56.5 ± 2.90.76
Duration of illness (month)39.3 ± 27.433.25 ± 28.40.46
Sex: male/female8/838/60.003
Type of NS (clinical situation at enrollment) < 0.001
    First attack230
    SDNS04
    FRNS22
    SRNS128
Degree of edema0.18
    Puffy eyes + LL edema + Ascites520
    As 1 + Scrotal or vulval edema822
    1 or 2 + Pleural effusion32
Outcome of edema: Resolved13430.024
                               Nonresolved31
Percentage of weight reduction until edema resolution (%)16.9 ± 11.311.1 ± 7.040.02
SBP (mm Hg) at the time of enrollment105.3 ± 10.5111.4 ± 12.20.04
DBP (mm Hg) at the time of enrollment71.6 ± 14.271.05 ± 12.20.88
Heart rate (/m) at the time of enrollment94.2 ± 10.589.8 ± 9.70.13
Serum albumin (g/dL)1.95 ± 0.481.7 ± 0.260.04
Serum creatinine (mg/dL)0.46 ± 0.140.58 ± 0.20.024
Serum Na (mEq/L)131.4 ± 5.6137.3 ± 5.40.001
BUN (mg/dL)19.4 ± 3.316.2 ± 4.10.007
FeNa (%)0.16 ± 0.121.59 ± 0.67 < 0.001
Plasma ANP (pg/mL)132.97 ± 59.2127.9 ± 51.70.7
Hemoglobin (g/dL)13.1 ± 1.311.1 ± 12 < 0.001
Hematocrit (%)43.8 ± 3.337.8 ± 7.90.005
Expiratory IVC diameter (mm)9.9 ± 2.910.04 ± 1.580.8
Inspiratory IVC diameter (mm)4.7 ± 0.56.99 ± 1.52 < 0.001
IVCCI on admission48.97 ± 10.230.37 ± 10.98 < 0.001
BCM-OH1.5 (1.95)*2.2 (1.9)*0.01

*presented as median and interquartile range

Bold values indicate statistically significant values (below 0.05)

ANP Atrial natriuretic peptide, BCM Body composition monitor, BUN Blood urea nitrogen, DBP Diastolic blood pressure, FRNS Frequent relapsing nephrotic syndrome, FeNa% Fractional excretion of sodium, IVC Inferior vena cava, IVCCI Inferior vena cava collapsibility index, NS Nephrotic syndrome, OH Over hydration, SBP Systolic blood pressure, SDNS Steroid-dependent nephrotic syndrome, SRNS Steroid-resistant nephrotic syndrome

Clinical and laboratory data of hypovolemic vs. nonhypovolemic patients with active INS at the time of initial enrollment in the study and after resolution of edema *presented as median and interquartile range Bold values indicate statistically significant values (below 0.05) ANP Atrial natriuretic peptide, BCM Body composition monitor, BUN Blood urea nitrogen, DBP Diastolic blood pressure, FRNS Frequent relapsing nephrotic syndrome, FeNa% Fractional excretion of sodium, IVC Inferior vena cava, IVCCI Inferior vena cava collapsibility index, NS Nephrotic syndrome, OH Over hydration, SBP Systolic blood pressure, SDNS Steroid-dependent nephrotic syndrome, SRNS Steroid-resistant nephrotic syndrome

Discussion

There are multiple limitations of the use of urinary indices in edema status evaluation in INS, including use of diuretics, antihypertensives, and dietary salt intake [7]. This is why the search is continuous for other simple accurate tools for evaluation of volume status in INS patients. Brantlov and colleagues reported the valuable use of BCM to distinguish children with active NS from well-treated and healthy children [7], and also Ozdemir et al. [4] reported significant differences in volume burden assessment by BCM between INS children with localized versus those with generalized edema. However, BCM showed moderate sensitivity and specificity for identifying hypervolemia and was nondiscriminative for hypovolemia. BCM can detect the presence and the severity of volume load but cannot define site of extra fluids, and consequently, can be used to monitor response to edema treatment; however, its role in differentiating edema type is limited. Former studies regarding usefulness of IVCCI in volume evaluation in INS showed contradictory results. In accordance with the results of the present study, Tabel and colleagues observed IVCCI values were significantly increased with diuretic therapy; patients changed from hypervolemia to euvolemic state [8]. Donmez et al. [2] studied the value of IVCCI to determine the volume load in children with minimal lesion NS and noted that IVCCI in edematous patients was less than in nonedematous group and healthy control group, indicating hypervolemic state in edematous patients. To assess the discriminative value of IVCCI as indicator of volume status in active NS, ROC curve was plotted showing a cutoff point 37.5, with an AUC of 0.88, i.e., very good discriminator; more than this point refers to hypovolemic state; and less indicates nonhypovolemia, with sensitivity = 75% and specificity = 86%. However, Ozdemir et al. [4] concluded that using the IVCCI to determine volume load, the sensitivity was 95% and the specificity was 10% and that BIS may be superior to IVCCI in determining volume load in children with INS, which is also against the results of the present study. Plasma ANP concentration elevation did not reach significant difference between hypovolemic and nonhypovolemic groups. This indicates that ANP plays a role in edema formation in active NS but not in the exact type of edema, and there is some sort of renal resistance to ANP diuretic and natriuretic actions. In NS, resistance to serum ANP is an observation in experimental animals and humans [9, 10], and these studies showed that ANP levels were frequently elevated in INS children as compared to in healthy or remission children.

Conclusion

Assessment of hydration status in INS children is critical for management of edema. IVCCI is a sensitive and specific tool for discriminating type of edema in INS and is superior to BCM, while serum ANP levels do not seem to be differentiating for the type of edema in INS.
  10 in total

1.  Inferior vena cava indices determine volume load in minimal lesion nephrotic syndrome.

Authors:  O Dönmez; S Mir; R Ozyürek; A Cura; C Kabasakal
Journal:  Pediatr Nephrol       Date:  2001-03       Impact factor: 3.714

2.  Changes of atrial natriuretic Peptide system in rats with puromycin aminonucleoside-induced nephrotic syndrome.

Authors:  Eun Hui Bae; Jongun Lee; Seong Kwon Ma; Soo Wan Kim
Journal:  Korean J Physiol Pharmacol       Date:  2009-02-28       Impact factor: 2.016

3.  Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome.

Authors:  J Plum; Y Mirzaian; B Grabensee
Journal:  Nephrol Dial Transplant       Date:  1996-06       Impact factor: 5.992

4.  Hypo- and hypervolemic edema in children with steroid sensitive nephrotic syndrome.

Authors:  Mehmet Akif Büyükavci; Mahmut Çivilibal; Murat Elevli; Hatice Nilgün Selçuk Duru
Journal:  Turk J Med Sci       Date:  2015       Impact factor: 0.973

5.  Bioimpedance for assessing volume status in children with nephrotic syndrome.

Authors:  Kadriye Özdemir; Makbule Sevgi Mir; Nida Dinçel; Sibel Bozabali; İpek Kaplan Bulut; Ebru Yilmaz; Betül Sözeri
Journal:  Turk J Med Sci       Date:  2015       Impact factor: 0.973

6.  Atrial natriuretic factor in idiopathic minimal-lesion nephrotic syndrome.

Authors:  E H Garin; R V Paul
Journal:  Child Nephrol Urol       Date:  1990

7.  Treatment of severe edema in children with nephrotic syndrome with diuretics alone--a prospective study.

Authors:  Gaurav Kapur; Rudolph P Valentini; Abubakr A Imam; Tej K Mattoo
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

8.  Is edema in minimal change disease of childhood really hypovolemic?

Authors:  Yilmaz Tabel; Ilke Mungan; Cemsit Karakurt; Gulendam Kocak; Serdal Gungor
Journal:  Int Urol Nephrol       Date:  2008-04-15       Impact factor: 2.370

9.  Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans.

Authors:  C Peterson; B Madsen; A Perlman; A Y Chan; B D Myers
Journal:  Kidney Int       Date:  1988-12       Impact factor: 10.612

10.  Bioimpedance Resistance Indices and Cell Membrane Capacitance Used to Assess Disease Status and Cell Membrane Integrity in Children with Nephrotic Syndrome.

Authors:  Steven Brantlov; Lars Jødal; René Frydensbjerg Andersen; Aksel Lange; Søren Rittig; Leigh C Ward
Journal:  ScientificWorldJournal       Date:  2019-05-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.